Ocugen Provides Business Update with First Quarter 2023 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber... | May 5, 2023
United States Shankar Musunuri Ocugen Inc Exchange Commission Head Of Communications Conference Call
Source: marketscreener.com